• Overview
  • Eligibility
  • More info
  • Locations

(NCT02896413)

Surgical stress and anesthesia may cause immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. Dexmedetomidine has sympatholytic effect and preserves NK cell function. This study investigate the effect of dexmedetomidine on immune suppression and postoperative outcomes in patients undergoing uterine cancer resection.
  • Drug: Dexmedetomidine group
    dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
    • Drug: Control group
      0.9% saline infusion
      Ages eligible for Study
      20 Years to 70 Years
      Genders eligible for Study
      Female
      Accepts Healthy Volunteers
      No
      Inclusion Criteria:
      • patient between 20 and 70 of age with ASA physical status Ⅰ-Ⅲ
      • patient scheduled for uterine cancer surgery
      Exclusion Criteria:
      • ASA physical status Ⅳ
      • severe hepatorenal disease
      • infection
      • metastasis to other organ
      • problem with communication

      1 locations

      Korea, Republic of (1)
      • Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine
        recruiting
        Seoul, Korea, Republic of, 03722
      Status:
      recruiting
      Type:
      Interventional
      Phase:
      -
      Start:
      30 April, 2016
      Updated:
      05 September, 2016
      Participants:
      100
      Apply
      A girl giving information about available additional trials.

      FindMeCure helps you find, understand and join clinical trials from all over the world.

      There are more clinical trials for your condition!